Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01355393
What this trial is testing

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+5 more
University of Washington 50
Large-scale testing (Phase 3)Looking for participantsNCT05910398
What this trial is testing

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

Who this might be right for
Breast Cancer Invasive
RenJi Hospital 488
Testing effectiveness (Phase 2)UnknownNCT04659499
What this trial is testing

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Who this might be right for
Early Breast Cancer
Peking Union Medical College Hospital 261
Not applicableUnknownNCT04288141
What this trial is testing

Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies

Who this might be right for
HER2-positive Breast Cancer
King's College London 40
Testing effectiveness (Phase 2)Study completedNCT01688609
What this trial is testing

Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

Who this might be right for
HER2-positive Breast CancerStage II Breast CancerStage IIIA Breast Cancer
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)UnknownNCT03812393
What this trial is testing

Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Who this might be right for
Triple Negative Breast CancerEarly-stage Breast CancerHER2-positive Breast Cancer
West Cancer Center 27
Large-scale testing (Phase 3)Study completedNCT03969121
What this trial is testing

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Who this might be right for
Breast Cancer FemaleHormone Receptor Positive Malignant Neoplasm of Breast
Kyoto Breast Cancer Research Network 141
Testing effectiveness (Phase 2)Looking for participantsNCT07233499
What this trial is testing

Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients

Who this might be right for
HER2-positive Breast Cancer
Ain Shams University 56
Early research (Phase 1)Looking for participantsNCT06414733
What this trial is testing

HER-2 B Cell Peptide Vaccine

Who this might be right for
Metastatic Breast CancerHER2-positive Breast CancerEGFR Overexpression+2 more
Pravin T.P Kaumaya 42
Not applicableUnknownNCT04765124
What this trial is testing

The Efficacy and Safety of Neoadjuvant Trastuzumab Plus Taxane With and Without Pertuzumab Therapy

Who this might be right for
Breast Cancer
Ahmet Bilici 1,500
Testing effectiveness (Phase 2)UnknownNCT05880927
What this trial is testing

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Taizhou Hospital 150
Large-scale testing (Phase 3)UnknownNCT01104571
What this trial is testing

Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 257
Early research (Phase 1)Study completedNCT03135171
What this trial is testing

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 11
Early research (Phase 1)Study completedNCT00436254
What this trial is testing

Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer

Who this might be right for
HER2-positive Breast CancerStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell Tumor+6 more
University of Washington 66
Not applicableStudy completedNCT06149377
What this trial is testing

Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer

Who this might be right for
Breast CancerSentinel Lymph Node
Fujian Medical University Union Hospital 716
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Testing effectiveness (Phase 2)Study completedNCT03140553
What this trial is testing

TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer

Who this might be right for
HER2-Positive Breast Cancer
Guangdong Provincial People's Hospital 140
Not applicableNo Longer AvailableNCT03424473
What this trial is testing

Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

Seagen Inc.
Not applicableUnknownNCT05912062
What this trial is testing

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerNeoplasmsBreast Cancer
Institut Català d'Oncologia 80
Testing effectiveness (Phase 2)Study completedNCT01441596
What this trial is testing

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Boehringer Ingelheim 121
Next Page